Over the last five years, large data sets on mortality in schizophrenia have been published which have established mortality as a measurable clinical endpoint. Four issues need clarification: whether mortality rates are declining, what the causes of death are, the effects antipsychotic treatments have on mortality and whether these data inform as to how mortality may be reduced in the future. A PubMed search was carried out to identify relevant publications. The search strategy was conducted as a review focusing predominantly on data since 2006. A large number of retrospective epidemiological and prospective studies have been published on mortality rates and causation in schizophrenia, predominantly from 2006—2009. Data suggest that the mortality gap with the general population increased from the 1970s but may have peaked in the mid-1990s. The main causes of mortality are suicide, cancer and cardiovascular disease, with evidence that cancer mortality rates are similar to cardiovascular mortality rates. Mortality causation is dependent upon age of the cohort, length of follow up and type of study. Antipsychotic treatments reduce mortality when compared with no treatment and atypical antipsychotics do not appear to increase cardiovascular mortality and morbidity compared with conventionals; further research is required for any definitive conclusion.
Alaräisänen A., Miettunen J., Räsänen P., Fenton W., KoivumaaHonkanen HT and Isohanni M. ( 2009) Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc Psychiatry Psychiatr Epidemiol44: 1107-1110.
2.
Allebeck P., Brandt L., Nordstrom P. and Asgard U. ( 1996) Are suicide trends among the young reversing? Age, period and cohort analyses of suicide rates in Sweden. Acta Psychiatr Scand93: 43-48.
3.
Baandrup L., Gasse C., Jensen VD, Glenthoj BY, Nordentoft M., Lublin H., et al. (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry71: 103-108.
4.
Barnett AH, Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., et al. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol21: 357-373.
5.
Brown S. ( 1997) Excess mortality of schizophrenia. A meta-analysis . Br J Psychiatry171: 502-508.
6.
Brown S., Inskip H. and Barraclough B. ( 2000) Causes of the excess mortality of schizophrenia . Br J Psychiatry177: 212-217.
7.
Brown S., Kim M., Mitchell C and Inskip H (2010) Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry196: 116-121.
8.
Bushe CJ, Bradley AJ, Wildgust HJ and Hodgson RE(2009) Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res114(1-3): 6-16.
9.
Bushe C. and Leonard B. ( 2004) Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry Suppl47: S87-S93.
10.
Bushe CJ and Leonard BE ( 2007) Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry68: 1682-1690.
11.
Caldwell CB and Gottesman II ( 1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull16: 571-589.
12.
Capasso RM, Lineberry TW, Bostwick JM, Decker PA and St Sauver J. ( 2008) Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res98: 287-289.
13.
Catts VS, Catts SV, O’Toole BI and Frost ADJ ( 2008) Cancer incidence in patients with schizophrenia and their first-degree relatives-a meta-analysis. Acta Psychiatr Scand117: 323-336.
14.
Chong SA, Tay JA, Subramaniam M., Pek E and Machin D (2009) Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol29: 5-8.
15.
Colton CW and Manderscheid RW ( 2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis3: A42.
16.
Dalton SO, Steding-Jessen M., Engholm G., Schüz J. and Olsen JH ( 2008) Social inequality and incidence of and survival from lung cancer in a population-based study in Denmark, 1994-2003. Eur J Cancer44: 1989-1995.
17.
De Hert M., Correll CU and Cohen D (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res117: 68-74.
18.
Dean CE and Thuras PD(2009) Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br J Psychiatry194: 360-364.
19.
Drew LR ( 2005) Mortality and mental illness. Aust N Z J Psychiatry39: 194-197.
20.
Enger C., Weatherby L., Reynolds RF, Glasser DB and Walker AM ( 2004) Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis192: 19-27.
21.
Fors BM, Isacson D., Bingefors K. and Widerlöv B. ( 2007) Mortality among persons with schizophrenia in Sweden: an epidemiological study. Nord J Psychiatry61: 252-259.
22.
Graunt J. ( 1662) Natural and political observations mentioned in a following index, and made upon the bills of mortality. In: Hunter RA and Macalpine I (eds) ( 1963) Three Hundred Years of Psychiatry . London: Oxford University Press , 166.
23.
Harris EC and Barraclough B. ( 1998) Excess mortality of mental disorder. Br J Psychiatry173: 11-53.
24.
Haukka J., Tiihonen J., Härkänen T. and Lönnqvist J. ( 2008) Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia . Pharmacoepidemiol Drug Saf17: 686-696.
25.
Healy D., Harris M., Tranter R., Gutting P., Austin R., Jones-Edwards G., et al. (2006) Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. Br J Psychiatry188: 223-228.
26.
Heilä H., Haukka J., Suvisaari J. and Lönnqvist J. ( 2005) Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med35: 725-732.
27.
Hennekens CH, Hennekens AR, Hollar D. and Casey DE ( 2005) Schizophrenia and increased risks of cardiovascular disease . Am Heart J150: 1115-1121.
28.
Hippisley-Cox J., Vinogradova Y., Coupland C. and Parker C. ( 2007) Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry64: 1368-1376.
29.
Isaac M. and Koch A.(2010) The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. Eur Neuropsychopharmacol20: 139-145.
30.
ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet2: 349-360.
31.
Johansson LA and Westerling R. ( 2000) Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol29: 495-502.
32.
Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R. and Lehtinen V. ( 2006) Schizophrenia, neuroleptic medication and mortality . Br J Psychiatry188: 122-127.
33.
Kahn RS, Fleischhacker WW, Boter H., Davidson M., Vergouwe Y., Keet IPM, et al., for the EUFEST study group ( 2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial . Lancet371: 1085-1097.
34.
Kelly DL, McMahon RP, Liu F., Love RC, Wehring HJ, Shim JC, et al. (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry71: 304-311.
35.
Khan A., Schwartz K., Stern C., Redding N., Kolts RL, Brown WA, et al. (2007) Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. J Clin Psychiatry68: 1828-1833.
36.
Kisely S., Campbell LA and Wang Y (2009) Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry195: 545-550.
37.
Kiviniemi M., Suvisaari J., Pirkola S., Häkkinen U., Isohanni M and Hakko H (2010) Regional differences in five-year mortality after a first episode of schizophrenia in Finland. Psychiatr Serv61: 272-279.
38.
Lahti RA and Penttilä A. ( 2001) The validity of death certificates: routine validation of death certification and its effects on mortality statistics. Forensic Sci115: 15-32.
39.
Laursen TM, Munk-Olsen T., Agerbo E., Gasse C. and Mortensen PB ( 2009) Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry66: 713-712.
40.
Laursen TM, Munk-Olsen T., Nordentoft M. and Mortensen PB ( 2007) Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry68: 899-907.
41.
Lawrence DM, Holman CD, Jablensky AV and Hobbs MS ( 2003) Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry182: 31-36.
42.
Lawrence D., Holman CD, Jablensky AV, Threlfall TJ and Fuller SA ( 2000) Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand101: 382-388.
43.
Lawrence D., Mitrou F. and Zubrick SR(2009) Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health9: 285.
44.
Lichtermann D., Ekelund J., Pukkala E., Tanskanen A. and Lönnqvist J. ( 2001) Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry58: 573-578.
45.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . N Engl J Med353: 1209-1223.
46.
Mortensen PB and Juel K. ( 1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry163: 183-189.
47.
Osborn DP, Levy G., Nazareth I., Petersen I., Islam A. and King MB ( 2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry64: 242-249. Erratum in: Arch Gen Psychiatry2007; 64: 736.
48.
Osby U., Correia N., Brandt L., Ekbom A. and Sparén P. ( 2000) Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ2000; 321: 483-484.
49.
Palmer BA, Pankratz VS and Bostwick JM ( 2005) The lifetime risk of suicide in schizophrenia: a reexamination . Arch Gen Psychiatry2005 ; 62: 247-253.
50.
Parks J., Svendsen D., Singer P. and Foti M. ( 2006) Morbidity and Mortality in People with Serious Mental Illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, Alexandria, VA 22314. Available at: www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011-06.pdf(accessed17March2010).
51.
Peuskens J., Tanghøj P. and Mittoux A. ( 2009) Outcome of the prospective sertindole prospective (SCOP) study. All-cause mortality. Schizophr Bull35: 347.
52.
Pompili M., Lester D., Grispini A., Innamorati M., Calandro F., Iliceto P., et al. (2009) Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res167: 251-257.
53.
Saha S., Chant D. and McGrath J. ( 2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry64: 1123-1131.
54.
Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet374: 620-627.
55.
Tiihonen J., Wahlbeck K., Lönnqvist J., Klaukka T., Ioannidis JP, Volavka J., et al. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ333: 224.
56.
Tran E., Rouillon F., Loze JY, Casadebaig F., Philippe A., Vitry F., et al. (2009) Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer115: 3555-3562.
57.
Tsuang MT, Woolson RF and Fleming JA ( 1980) Causes of death in schizophrenia and manic-depression . Br J Psychiatry136: 239-242.
58.
Weinmann S., Read J and Aderhold V (2009) Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res113: 1-11.
